Study links communication, outcomes in cancer

Print Friendly, PDF & Email


Doctor consults with cancer
patient and her father
Photo by Rhoda Baer
Better communication between cancer patients and healthcare providers may provide tangible benefits, according to research published in JNCCN. Cancer survivors who reported greater satisfaction in communicating with healthcare providers had better general health and mental health, fewer doctor visits, and reduced healthcare spending,... [Read Article]
Print Friendly, PDF & Email

Drug under priority review for BPDCN

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The US Food and Drug Administration(FDA) has accepted for priority review the biologics license application seeking approval for tagraxofusp (Elzonris, SL-401) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). The FDA expects to make a decision on this application by February 21, 2019. The FDA grants priority review... [Read Article]
Print Friendly, PDF & Email

Familial risk of myeloid malignancies

Print Friendly, PDF & Email


Three generations of
women in a family
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The study showed that first-degree relatives of patients with myeloid malignancies had double the risk of developing a myeloid malignancy themselves, when compared to the general population. The researchers... [Read Article]
Print Friendly, PDF & Email

Group releases new CLL guidelines

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
Fludarabine, cyclophosphamide, and rituximab are recommended as initial therapy for fit patients with chronic lymphocytic leukemia (CLL) who do not have TP53 disruption, according to new guidelines from the British Society for Haematology. The guidelines update the 2012 recommendations on CLL to include “significant” developments in treatment. The... [Read Article]
Print Friendly, PDF & Email

Ixazomib could improve treatment of AML

Print Friendly, PDF & Email


Lab mouse
New research suggests the FOXM1 protein plays an important role in acute myeloid leukemia (AML) progression, and targeting FOXM1 could improve AML treatment. With a retrospective study, researchers showed that overexpression of FOXM1 was associated with increased resistance to chemotherapy and inferior overall survival. Subsequent preclinical research showed that ixazomib inhibits FOXM1, exhibits... [Read Article]
Print Friendly, PDF & Email

Team recommends melanoma screening in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Patients with chronic lymphocytic leukemia (CLL) should be routinely monitored for melanoma, according to researchers. A study of 470 CLL patients showed they have a significantly higher risk of invasive melanoma than the general population. Most of the melanomas reported in this study were detected via routine surveillance, and most were discovered... [Read Article]
Print Friendly, PDF & Email

Frequent BCCs linked to blood cancers

Print Friendly, PDF & Email


Woman sunbathing
New research suggests people who develop frequent cases of basal cell carcinoma (BCC) have an increased risk of leukemias, lymphomas, and other cancers. “We discovered that people who develop 6 or more basal cell carcinomas during a 10-year period are about 3 times more likely than the general population to develop other, unrelated... [Read Article]
Print Friendly, PDF & Email

Drug could be repurposed for T-ALL

Print Friendly, PDF & Email


Micrograph showing T-ALL
© Hind Medyouf, German
Cancer Research Center
Venetoclax might improve the treatment of certain patients with T-cell acute lymphoblastic leukemia (T-ALL), according to preclinical research published in Leukemia. Researchers found that a ribosomal defect—the R98S mutation in ribosomal protein L10 (RPL10 R98S)—causes overexpression of BCL-2 in T-ALL. The BCL-2 inhibitor venetoclax induced... [Read Article]
Print Friendly, PDF & Email

Treatment guidelines for CAR T-cell therapy

Print Friendly, PDF & Email


CAR T cells
Photo from Penn Medicine
Researchers have developed treatment guidelines for pediatric patients receiving chimeric antigen receptor (CAR) T-cell therapy. The guidelines include recommendations for patient selection and consent, treatment details, and advice on managing cytokine release syndrome (CRS) and other adverse events associated with CAR T-cell therapy. The guidelines were published in... [Read Article]
Print Friendly, PDF & Email

Orphan designation recommended for PCM-075

Print Friendly, PDF & Email


AML cells
Image by Lance Liotta
The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has recommended that PCM-075 receive orphan drug designation as a treatment for acute myeloid leukemia (AML). PCM-075 is an oral adenosine triphosphate competitive inhibitor of the serine/threonine Polo-like kinase 1 (PLK1) enzyme, which is overexpressed in hematologic and... [Read Article]
Print Friendly, PDF & Email

Method may enable eradication of LSCs in AML

Print Friendly, PDF & Email


Micrograph showing LSCs
Image by Robert Paulson
Disrupting mitophagy may be a “promising strategy” for eliminating leukemia stem cells (LSCs) in acute myeloid leukemia (AML), according to researchers. The team found that AML LSCs depend on mitophagy to maintain their “stemness,” but targeting the central metabolic stress regulator AMPK or the mitochondrial dynamics regulator FIS1... [Read Article]
Print Friendly, PDF & Email

Adult CCSs report financial hardships

Print Friendly, PDF & Email


I-Chan Huang, PhD
Photo from St. Jude
Children’s Research
Hospital/Peter Barta
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the National Cancer Institute. Researchers analyzed more than 2800 long-term childhood cancer survivors (CCSs) and found that 65% had financial challenges related to their... [Read Article]
Print Friendly, PDF & Email

Inhibitor receives breakthrough designation for AML

Print Friendly, PDF & Email


AML cells
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to quizartinib, an investigational FLT3 inhibitor, for the treatment of adults with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). The FDA granted quizartinib breakthrough designation based on results from the phase 3 QuANTUM-R study, which were presented at the 23rd Congress of... [Read Article]
Print Friendly, PDF & Email

CHMP announces 2 opinions on blinatumomab

Print Friendly, PDF & Email


Vials of blinatumomab
powder and solution
Photo courtesy of Amgen
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has released 2 new opinions regarding blinatumomab (Blincyto). The CHMP recommended expanding the approved use of blinatumomab to include pediatric patients, but the committee also recommended against approving blinatumomab to treat patients with... [Read Article]
Print Friendly, PDF & Email